UK could allow reciprocal drug approvals with US FDA as soon as 2024
An intellectual property law firm says that recent guidance from the UK’s Medicines and Healthcare products Regulatory Agency hints at the possibility of the agency allowing approvals from other regulators, including possibly the US FDA, to play a role in UK regulatory processes.
Marks & Clerk, based out of London, wrote in a blog post that guidance from the UK’s regulatory agency from late January is providing more context into potential international collaboration with other regulators. How that would come about is after the UK’s “Reliance Procedure” — a way to ensure patients in Great Britain post-Brexit could still access new medicines — expires.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.